Last updated on July 2019

Long term, prospective, multinational, parallel-cohort study monitoring safety in patients with MS newly started on fingolimod once daily or treated with another approved disease-modifying therapy- PASSAGE- CFTY720D2403


Brief description of study

Long term, prospective, multinational, parallel-cohort study monitoring safety in patients with MS newly started on fingolimod once daily or treated with another approved disease-modifying therapy- PASSAGE- CFTY720D2403

Detailed Study Description

The purpose of this prospective parallel-cohort study in patients with relapsing forms of MS, either newly treated with fingolimod or receiving another disease-modifying therapy, is to further monitor the overall safety profile of fingolimod under conditions of routine medical practice and to explore the incidence of selected safety related outcomes.

The study is also meant to address other specific questions, via several sub-studies. This includes a PRO sub study, a pulmonary sub-study, a cardiac sub-study (for fingolimod treated patients only) and a resource utilization sub-study in Canadian patients.

Clinical Study Identifier: TX140477

Find a site near you

Start Over

Baptist Health Lexington Clinical Research Center

1740 Nicholasville Road Lexington, KY USA
  Connect »